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Slow Wallerian degeneration (WldS) mutant mice express a chimeric nuclear protein that protects sick or injured axons
from degeneration. The C-terminal region, derived from NAD synthesizing enzyme Nmnat1, is reported to confer
neuroprotection in vitro. However, an additional role for the N-terminal 70 amino acids (N70), derived from multiubiq-
uitination factor Ube4b, has not been excluded. In wild-type Ube4b, N70 is part of a sequence essential for ubiquitination
activity but its role is not understood. We report direct binding of N70 to valosin-containing protein (VCP; p97/Cdc48), a
protein with diverse cellular roles including a pivotal role in the ubiquitin proteasome system. Interaction with WldS
targets VCP to discrete intranuclear foci where ubiquitin epitopes can also accumulate. WldS lacking its N-terminal 16
amino acids (N16) neither binds nor redistributes VCP, but continues to accumulate in intranuclear foci, targeting its
intrinsic NAD synthesis activity to these same foci. Wild-type Ube4b also requires N16 to bind VCP, despite a more
C-terminal binding site in invertebrate orthologues. We conclude that N-terminal sequences of WldS protein influence the
intranuclear location of both ubiquitin proteasome and NAD synthesis machinery and that an evolutionary recent
sequence mediates binding of mammalian Ube4b to VCP.
INTRODUCTION
The E4 ubiquitination factor Ube4b (or Ufd2a) has a 123-
amino acid N-terminal region that is essential for ubiquiti-
nation activity (Mahoney et al., 2002). It is unclear why this
region is essential because it does not contain the U box, and
it appears to be absent in invertebrate orthologues that
ubiquitinate effectively (Koegl et al., 1999; Hatakeyama et al.,
2001; Mahoney et al., 2002; Hoppe et al., 2004; Richly et al.,
2005). It is important to understand the molecular mecha-
nism of Ube4b because it has a key role in the ubiquitin
proteasome system (UPS; Hoppe, 2005), it is neuroprotective
in polyglutamine disorders (Matsumoto et al., 2004) and an
important candidate gene for neuroblastoma (Krona et al.,
2003). Information on the substrates of Ube4b is beginning to
emerge (Hoppe et al., 2004; Okumura et al., 2004; Spinette et
al., 2004; Richly et al., 2005) but there is much still to learn
about its regulation.
In the slow Wallerian degeneration mutant mouse (WldS),
70 amino acids of this essential domain of Ube4b form the
N-terminus of a chimeric protein that delays Wallerian de-
generation of injured axons in mice and rats by 10-fold (see
Figure 1A; Lunn et al., 1989; Mack et al., 2001; Adalbert et al.,
2005). The chimeric protein is absent in wild-type mice. This
sequence (N70) is fused in WldS protein to the full coding
sequence of nicotinamide mononucleotide adenylyltrans-
ferase (Nmnat1; Conforti et al., 2000; Emanuelli et al., 2001;
Mack et al., 2001), implicating the UPS or NAD metabolism
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in regulating axon degeneration. WldS also delays axon
degeneration in a wide range of neurodegenerative disor-
ders and acute retrograde axonal degeneration after spinal
injury, indicating that axon degeneration mechanisms are
more closely related than previously thought (Wang et al.,
2002; Ferri et al., 2003; Samsam et al., 2003; Coleman, 2005;
Kerschensteiner et al., 2005; Mi et al., 2005). Surprisingly,
WldS in vivo has only been found in nuclei, suggesting that
downstream axonal effector(s) mediate its remarkable effect
on axon degeneration (Mack et al., 2001; Samsam et al., 2003;
Sajadi et al., 2004).
Nmnat1 activity was reported to preserve injured axons for
3 d in vitro (Araki et al., 2004; Wang et al., 2005). However,
axons in vivo are far longer, have a profoundly different envi-
ronment, and are protected by full-length WldS for up to 3 wk
(Crawford et al., 1995; Adalbert et al., 2005). A contribution of
N70 to strengthening the neuroprotective phenotype in vivo is
suggested by the fact that transgenic mice overexpressing
Nmnat1 show a normal rate of Wallerian degeneration
(Coleman and Perry, 2002; Conforti and Coleman, unpublished
data). N70 could contribute to neuroprotection by perturbing
the UPS, which is important for regulating axon degeneration
(Zhai et al., 2003; Macinnis and Campenot, 2005). Alternatively,
it could influence intranuclear targeting of Nmnat1, with its
intrinsic NAD synthesis activity, as WldS protein clusters to
discrete intranuclear foci in skeletal muscle (Mack et al., 2001)
and in many neuronal subtypes in vivo (Haley et al., unpub-
lished results). The inability of successive investigators to de-
tect any increase in NAD level when Nmnat1 is manipulated
(Mack et al., 2001; Anderson et al., 2002; Araki et al., 2004)
suggests that NAD is synthesized at highly localized intranu-
clear sites or immediately is passed to downstream compo-
nents within the same complex. Either way, intranuclear tar-
geting should be important.
To understand better the function of N70 in both WldS and
Ube4b proteins, we sought N70 binding partners. We identi-
fied valosin containing protein (VCP) as a direct binding part-
ner of N70 that becomes targeted to discrete intranuclear foci
when WldS protein is present. VCP, one of the AAA family of
ATPases associated with a variety of activities, has critical roles
in the UPS (Dai and Li, 2001; Jarosch et al., 2002; Wang et al.,
2004) and many other cellular roles dictated by interacting
proteins (Meyer et al., 2000; Mogk et al., 2004; Wang et al., 2004).
It accumulates in neuronal nuclei in a range of neurodegenera-
tive diseases and can influence neurodegeneration both posi-
tively and negatively (Hirabayashi et al., 2001; Higashiyama et
al., 2002; Mizuno et al., 2003; Watts et al., 2004; Schroder et al.,
2005). Its intranuclear roles include interaction with Werner
protein to influence the DNA damage response pathway (In-
dig et al., 2004) and the nuclear import of the T-cell-specific
adaptor protein (Marti and King, 2005). Our data suggest the
possibility of further intranuclear roles for VCP and an impor-
tant function for the N70 domain in both wild-type Ube4b and
WldS proteins.
MATERIALS AND METHODS
Constructs
VCP full-length cDNA was PCR-amplified with the Expand High Fidelity
PCR System (Roche, Mannheim, Germany) from a mouse fibroblast cDNA
library (kindly provided by R. Lange) using the 5 BamHI- and 3 SalI-tagged
primers (restriction sites in bold): 5-ATATATGGATCCCCATGGCCTCTG-
GAGCCGATTC-3; 5-AATATTGTCGACTTAGCCATACAGGTCATCGTC-3.
The products were cloned with BamHI/SalI into pGEX5X-1 (Amersham
Biosciences, Freiburg, Germany), and with NcoI/SalI into the pGBKT7 vector
(BD Biosciences Clontech, Heidelberg, Germany). The WldS protein, N70 and
further truncation products were similarly PCR-amplified and cloned using
the WldS transgene construct (Mack et al., 2001) as template and appropriate
primers based on the WldS cDNA (GenBank AF260924). Human Ube4b was
amplified from a construct kindly provided by Professor James Mahoney
using primers 5-ATCCCGGAATTCATGGAGGAGCTGAGCGCTGAT-3
and 5-CCGCCTCGAGTTAGTGATCGCTGTTCTGTTT-3 (EcoRI and XhoI
sites for cloning into pGEX5X-1 in bold). cDNA sequence encoding full-length
WldS protein, Nmnat-1 or Ube4b amino acids 1–70 (N70) was PCR-amplified
from the WldS transgene template (Mack et al., 2001) using the high-fidelity
enzyme Pfu (Stratagene, Heidelberg, Germany) and appropriate combina-
tions of the following primers (1  2, 4  2, and 1  3, respectively). 5
restriction enzyme tags, added for cloning purposes, are shown in bold and
the first or last three bases of sequence derived from the WldS gene are
underlined. A single base change to repress the stop codon of WldS Rev and
allow read-through of the C-terminal EGFP is double-underlined: 1) 5-
TAGATCCCAAGCTTAACCTTTCACCATTAAGAGGAAAGCGATG-3; 2)
5-GCGGGATCCCGTCCCAGAGTGGA-
ATGGTTGTG-3; 3) 5-TCCTCCCCGCGGGTCTGCTGCACCTATGGGGGA-
3; and 4) 5-GACTAGCTAGCATGGACTCATCCAAGAAGACAG-3.
After cloning of pEGFP-N1 (BD Biosciences), all sequences were verified
using the Taq FS BigDye-terminator cycle sequencing method on a ABI 377
prism sequencer and the corresponding ABI software. The sequences were
analyzed using the GCG program Wisconsin Package Version 10.2 (Accelrys,
San Diego, CA).
Full-length WldS DsRed construct was generated by cloning the HindIII/
BamHI insert from pEGFP-N1 (above) into pDsRed2-N1 (BD Biosciences).
WldS lacking N16 was generated using the following HindIII and BamHI-
tagged primers: 5-TAGCCCAAGCTTTAGGCCGCCACCATGCTTGCTG-
GTGGACAGACCT-3; 5-GCGGGATCCCGTCCCAGAGTGGAATGGTTG-3.
Pulldown Assays
C57BL/6J mouse brain homogenates were used in this experiment to avoid
competition from endogenous WldS protein. Brains were flash-frozen and
homogenized in 50 volumes of 50 mM Tris, pH 9.0, and 1% deoxycholate
containing protease inhibitor mix (Sigma, Taufkirchen, Germany). After in-
cubating for 30 min at 37°C, insoluble material was removed by centrifugation
(10,000  g, 30 min) and the supernatant was dialyzed against binding buffer
(50 mM Tris, pH 7.4, and 0.1% Triton X-100) overnight at 4°C. Homogenates
were incubated overnight at 4°C with GST fusion proteins bound to gluta-
thione Sepharose 4B. The beads were washed four times with phosphate-
buffered saline (PBS)/0.1% Triton X-100 and resuspended in 3 standard
Laemmli sample buffer. Proteins were separated by SDS-PAGE on 12% gels
and analyzed by Western blotting.
MALDI-TOF Mass Spectrometry
Proteins fished by a pulldown assay were eluted with double-concentrated
SDS-PAGE sample buffer and separated by SDS-PAGE. From the gel individ-
ual Coomassie blue-stained protein bands were excised with a scalpel and
destained by washing with 25 mM NH4HCO3/50% acetonitrile. For MALDI-
TOF mass spectrometry analysis, the samples were dissolved in 5 l 0.1%
aqueous trifluoroacetic acid. MALDI-MS was carried out in linear mode on a
Bruker Reflex IV equipped with a video system (Rheinstetten, Germany), a
nitrogen UV laser (Omax  337 nm), and a HiMass detector. One microliter
of the sample solution was placed on the target and 1 l of a freshly prepared
saturated solution of sinapinic acid in acetonitrile/H2O (2:1) with 0.1% trif-
luoroacetic acid was added. The spot was then recrystallized by addition of
another 1 l acetonitrile/H2O (2:1), which resulted in a fine crystalline matrix.
For recording of the spectra an acceleration voltage of 20 kV was used, and the
detector voltage was adjusted to 1.9 kV. Approx. 500 single laser shots were
summed into an accumulated spectrum. Calibration was carried out using the
single and doubly protonated ion signal of bovine serum albumin for external
calibration. Identification of the mass fingerprint spectra was performed using
the Mascot program available from Matrix Science on the World Wide Web
(http://www.matrixscience.com/home.html).
Isolation and Immunoprecipitation of Nuclear Proteins
Six mouse brains (ca. 2.5 g) were each homogenized using a Dounce homog-
enizer in 40 ml precooled nuclear isolation medium (NIM; 0.25 M sucrose, 25
mM KCl, 5 mM MgCl2, 10 mM Tris/HCl, pH 7.4) supplemented with pro-
tease inhibitor cocktail (Sigma). Unbroken cells and connective tissue were
removed by filtration. The filtered homogenate was then diluted with an
equal volume of ice-cold NIM, centrifuged (10 min, 800  g) and the pellet,
including lipids, was resuspended in 40 ml NIM supplemented with protease
inhibitor cocktail. After repeating the centrifugation, the new pellet was
resuspended in 8 ml NIM, 2 ml sucrose density barrier (SDB; 2.3 M sucrose,
25 mM KCl, 5 mM MgCl2, 10 mM Tris/HCl, pH 7.4) solution was added and
mixed thoroughly. 10 ml of the suspension was underlayered with 2.3 M
sucrose and centrifuged for 1 h at 100,000  g in a Beckman SW41 Ti rotor
(Krefeld, Germany). The pellet, together with remaining lipids, was resus-
pended in PBS containing 1% Triton X-100 and incubated for 2 h at 4°C with
continuous agitation. Samples were then centrifuged at 16,000 g to generate
a supernatant containing solubilized nuclear proteins.
For the subsequent immunoprecipitation, protein lysates were preincu-
bated with 30 l of protein G agarose (Roche) for 2 h at 4°C under constant
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agitation. Samples were centrifuged (5 min, 500g) to remove proteins unspe-
cifically bound to the protein G agarose and 3 l of anti-WldS rabbit serum
and another 30 l of protein G agarose were then added and incubated
overnight at 4°C with constant agitation. The precipitated proteins bound to
protein G agarose were then repeatedly washed by centrifugation at 500  g
at 4°C for 5 min. The final pellet was resuspended in 1 ml PBS, 1% Triton
X-100. Samples were then analyzed by SDS-PAGE and immunoblotting.
In Vitro Binding Assays
GST fusion proteins were purified and coupled to glutathione-Sepharose 4B
according to the protocol of the manufacturer (Amersham Biosciences). The
pGBKT7 constructs containing the T7 promoter were in vitro transcribed and
translated incorporating 35S-methionine using the TNT T7 Reticulocyte Lysate
Coupled Transcription/Translation kit from Promega (Promega GmbH,
Mannheim, Germany). The obtained proteins were mixed with equal
amounts of GST fusion proteins and the binding assay was performed as
previously described (Dai et al., 1998). Reactions were analyzed by SDS-
PAGE, and the gel was fixed with 10% methanol/10% acetic acid before
autoradiography. Purified His-tagged VCP was a kind gift from Dr. Sarah
Spinette (Johns Hopkins).
Cell Culture and Transfection
Plasmid DNA was isolated using the endonuclease free plasmid kit (QIAGEN,
Hilden, Germany). DNA was transfected using LipofectAMINE 2000 (Invitro-
gen) into COS-7, PC12, or HeLa cells immediately before differentiation by
culturing in 100 ng/l NGF on a type IV collagen substrate (Sigma). The “TV”
PC12 subline, stably transfected with a tet-off inducible C-terminal EGFP-tagged
VCP construct (Kobayashi et al., 2002) was grown in 1.0 g/ml doxycycline
(Sigma), which was removed to induce VCP/EGFP expression. Protein location
was observed 1–5 d after transfection. Spinal motor neurons from embryonic day
14 (E14) embryonic rats were cultured and electroporated in suspension as
previously described (Henderson et al., 1995; Raoul et al., 2002).
Immunocytochemistry
Slices of 100 m were cut from the cerebellum of WldS mice and fixed in 4%
paraformaldehyde (Fisher, Schwerte, Germany). Lumbar spinal cord dorsal
root ganglia (DRG) were removed from WldS mice or rats and fixed in 4%
paraformaldehyde, and then 20-m sections cut on a cryostat. Slices were
incubated for 2 h at room temperature in serum blocker consisting of 4%
bovine serum albumin (Sigma) and 0.5% Triton X-100 (Sigma) in PBS. Wld-18
antibody (Samsam et al., 2003; 1:500 dilution) plus VCP antibody (against
amino acids 9–130; BD Biosciences; 1:200 dilution; or mouse monoclonal to
VCP (ab11433); AbCam, Cambridge, United Kingdom, 1:500 dilution) were
applied simultaneously in serum blocking solution overnight at 4°C. After
washing with PBS, slices were incubated overnight at 4°C in a solution
containing TRITC-conjugated anti-rabbit (DAKO, Hamburg, Germany; 1:20
dilution in PBS) plus Alexa488-conjugated anti-mouse (Molecular Probes,
Leiden, Netherlands; 1:200) secondary antibodies. Slices were then washed in
PBS and incubated in To-pro3 (Molecular Probes) for 10 min before mounting
in Mowiol/DABCO preparation. Staining was visualized on a laser scanning
confocal microscope (Bio-Rad Radiance 2000, Hemel Hempsted, United King-
dom) and Z-series were merged using Lasersharp (Bio-Rad) software.
Cultured cells were fixed for 30 min in 4% paraformaldehyde, permeabil-
ized with Triton-X-100 (0.1%, 5 min), blocked with horse serum (5%, 1 h), and
incubated with primary (1 h) and secondary (45 min) antibodies with multiple
washes in PBS between each stage.
VCP antibody was used as described above. Anti-ubiquitin polyclonal
antibody (DAKO) was used at 1:100 dilution and anti-neurofilament medium
chain polyclonal antibody (Chemicon, Hofheim, Germany; Ab1987) was used
as 1:1000. Images were taken on a Zeiss LSM 510 META confocal system
(Oberkochen, Germany; LSM Software Release 3.2) coupled to a Zeiss Axio-
vert 200 microscope.
Western Blotting
WldS protein expression was analyzed in mouse cerebella homogenized in
five volumes of RIPA buffer, respectively, plus 1 Complete protease inhib-
itor cocktail (Roche) or in PC12 cells scraped from the dish in a minimal
volume of the same buffer. Proteins were separated by SDS-PAGE and
semidry blotted onto nitrocellulose (Bio-Rad). Blocking and incubation with
primary antibodies and horseradish peroxidase-conjugated secondary anti-
bodies (1:5000; Serotec, Heidelberg, Germany) were performed in PBS plus
0.02% Tween-20 and 5% low fat milk. Proteins were visualized using the ECL
detection kit (Amersham Biosciences) according to the manufacturer’s in-
structions.
RESULTS
WldS Protein Binds Directly to VCP through its N-
terminal Domain
A screen for WldS binding partners revealed that a protein of
ca. 97 kDa can be pulled down in large quantities from
mouse brain homogenate by GST-WldS (Figure 1B). N70 is
sufficient for this activity. Isolation of this protein from an
SDS-PAGE gel followed by MALDI-TOF mass spectrometry
protein identification revealed several tryptic peptides ex-
actly matching sequences from murine VCP (Figure 1C). To
confirm that binding of WldS to VCP is biologically relevant,
we coimmunoprecipitated VCP specifically from nuclear ex-
tracts of WldS mouse brain using antibody Wld-18 and con-
firmed the identity of VCP by Western blotting (Figure 1D).
VCP could not be coimmunoprecipitated from wild-type
mouse brain, which lacks WldS protein. The reciprocal co-
immunoprecipitation was inconclusive because VCP itself
was not immunoprecipitated by the BD Biosciences anti-
VCP antibody, but these data strongly suggest that the
WldS/VCP complex is biologically relevant. To determine
whether the binding was direct or mediated by other factors,
we precipitated purified His-tagged VCP (a kind gift from
Dr. Sarah Spinette and Prof. Antony Rosen, Johns Hopkins)
using GST-tagged N-terminal fragments of WldS (Figure 1E;
see also Figure 3). The ability of WldS-derived peptides to
precipitate VCP was retained in the absence of other rele-
vant proteins, showing that VCP binds directly to the shared
N-terminus of WldS and Ube4b. Because WldS protein has
been suggested to alter the UPS (Zhai et al., 2003; Coleman
and Ribchester, 2004), we then tested by Western blotting of
WldS and wild-type brain homogenates whether WldS alters
turnover of VCP, and thus its steady-state level, and found
that it does not (Figure 1F). Thus, VCP directly binds to WldS
protein through its N70 domain, and this binding does not
significantly alter steady-state level of VCP in brain.
WldS Colocalizes with and Partially Redistributes VCP
To investigate further whether WldS/VCP complexes form
inside living cells, we carried out colocalization studies in
vitro and in vivo. We took advantage of the fact that WldS
clusters into discrete intranuclear foci in some neuronal
subtypes (Haley et al., unpublished results) and other cells
(Mack et al., 2001; Figure 2). After transient transfection of
WldS/EGFP fusion construct into PC12 cells, VCP partially
shifted from the widespread nuclear and cytoplasmic distri-
bution that was previously described (Hirabayashi et al.,
2001; Kobayashi et al., 2002) and is present in untransfected
cells (Figure 2B, arrow) to produce the same pattern of
intranuclear foci as WldS (Figure 2B, arrowhead). VCP is an
abundant protein (Dai and Li, 2001), so the wider nuclear
and cytoplasmic pool remained without any obvious deple-
tion (Figure 2, A–C). VCP was also partially redistributed by
WldS in HeLa cells which, like PC12, remained healthy
(Supplementary Figures 2 and 4).
To study this in vivo, we made use of the finding that
cerebellar granule cells and molecular layer neurons also
show intranuclear foci of WldS protein, albeit of different
size and number from PC12 cells (Haley et al., unpublished
results). Again WldS and VCP colocalized within intranu-
clear foci in these neurons from WldS mice (Figure 2, D–F),
whereas in wild-type cerebellum, there were no intranuclear
VCP foci (Figure 2, G–I). Some DRG neurons in both WldS
mice and rats also showed good colocalization (Supplemen-
tary Figure 5), indicating that the WldS/VCP interaction
occurs in at least some neurons known to express the neu-
roprotective WldS phenotype and that this binding is con-
served between species. The situation is less clear in motor
neurons, where WldS is more homogenously distributed in
vivo (Mack et al., 2001; Samsam et al., 2003), and VCP colo-
calization with WldS spots was not evident in vitro (Supple-
mentary Figure 5). Nevertheless, the data are sufficient to
conclude that WldS and VCP bind one another under phys-
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iological conditions, including in at least some neurons that
display the WldS phenotype.
VCP Binds within the First 16 Residues of WldS
We show above that WldS binds to and partially redistrib-
utes VCP. To establish that binding causes redistribution, we
mapped and then deleted key residues of WldS required for
VCP binding. Truncated N70 constructs were expressed as
GST-fusion proteins and used to pull down IVTT-expressed
VCP. First the N-terminal 23 amino acids were found to be
necessary and sufficient for VCP binding, and this was sub-
sequently narrowed to the N-terminal 16 amino acids (N16;
Figure 3A). Ube4b lacking this sequence also did not bind
VCP. Two WldS/DsRed2 constructs were then made: one
full-length and one lacking N16, and transiently transfected
into the TV PC12 stable subline that expresses VCP/EGFP
fusion protein in a tet-off-inducible manner (a kind gift from
Prof. Akira Kakizuka). Full-length WldS/DsRed2 was able
to bring about partial redistribution of VCP/EGFP into in-
tranuclear foci in transfected cells (arrowhead; Figure 3,
B–E) but removal of N16 containing the VCP binding site
prevented this (Figure 3, F–I). Interestingly, the ability of
WldS protein to accumulate in intranuclear foci does not
require binding to VCP (Figure 3F). Thus, VCP has to bind
WldS N16 to be partially redistributed in the manner we
describe.
The Sequence Targeting WldS Protein to Intranuclear Foci
Is Not Nmnat1
Because VCP binding is not required to target WldS to
intranuclear foci, we asked whether this is a property of the
Nmnat1 sequence by fusing Nmnat1 to EGFP and tran-
siently transfecting it (Figure 4). Nmnat1, but not N70, was
restricted to the nucleus, confirming previous reports that
Figure 1. Direct binding of WldS/N70 sequence to VCP. (A) The N-terminal 70 amino acids of murine Ube4b (N70) are incorporated into
the neuroprotective, chimeric WldS protein, fused in-frame to the entire coding sequence (285 amino acids) of Nmnat1 and an 18-amino acid
linking region. In wild-type Ube4b, N70 forms part of a 123-amino acid sequence that is essential for ubiquitination activity. (B) A protein
of ca. 97 kDa was pulled down from wild-type mouse brain by GST-WldS and by GST-N70. Bottom panel, a Coomassie-stained gel of the
amounts of each protein used for pulldown, except that the GST sample has been diluted 1:10. The larger N70 and WldS proteins were
obtained in lower quantities but were still able to precipitate significant amounts of the 97-kDa protein. (C) Tryptic peptides of VCP were
identified by MALDI-TOF. Peptides marked with an asterisk (*), plus three additional VCP peptides (unpublished results), were present both
in the protein pulled down by N70 and in the one pulled down by WldS. (D) Coimmunoprecipitation of VCP with WldS protein. Antibody
Wld-18 was able to immunoprecipitate WldS protein (top) from nuclear extracts of mutant mouse brain (right) but not from wild-type mouse
brain (left). Coimmunoprecipitation of VCP showed the same pattern (middle), whereas control protein NeuN is not coimmunoprecipitated
(bottom) showing that the VCP result is specific. (E) Evidence that VCP binds directly to the N-terminus of WldS and Ube4b. Left,
Coomassie-stained gel showing purified VCP and its precipitation by WldS peptides; right, Western blot confirming identity of the
precipitated VCP and its complete absence in control lanes. The N-terminal 23 amino acids (N23) fused to GST (see also Figure 3) are able
to precipitate purified His-tagged VCP. Neither GST alone, nor amino acids 47–70 possess this specific binding activity. (F) VCP Western blot
of wild-type and WldS mouse brain homogenates showing that steady state levels of VCP are not altered by the presence of WldS. Below:
Coomassie stain showing equal loading. D–F are representative of at least two experiments.
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Nmnat1 is a nuclear protein and suggesting that nuclear
targeting of WldS protein is due to the putative nuclear
localization signal of Nmnat1 (Raffaelli et al., 2002; Araki et
al., 2004; Magni et al., 2004). However, unlike WldS/EGFP,
intranuclear distribution of Nmnat1/EGFP was homoge-
neous apart from its exclusion from nucleoli. The fraction of
N70/EGFP that entered the nucleus was also homoge-
neously distributed, suggesting that WldS protein is targeted
to intranuclear foci either by a conformational structure
involving both N70 and Nmnat1 sequence or by the short
unique sequence that separates these two parts of the pro-
tein. Cell and nuclear shape indicated that the cells were
healthy in all cases. We conclude that Nmnat1 and WldS
protein differ in their intranuclear distribution, but as shown
above, their differing abilities to bind VCP do not underlie
this difference.
WldS Also Can Partially Relocalize Ubiquitin inside the
Nucleus
VCP binds long ubiquitin chains (Dai and Li, 2001) so one
consequence of its partial redistribution by WldS protein
could be redistribution of bound polyubiquitinated proteins.
This was supported by immunocytochemistry of PC12 cells
transiently transfected with WldS/EGFP fusion construct
(Figure 5, A–H). As with VCP, the normal distribution of
ubiquitin throughout the nucleus and cytoplasm of untrans-
fected cells is joined by a punctate intranuclear pattern in
transfected cells, where ubiquitin puncta colocalize with
WldS/EGFP. Cell and nuclear shape indicated that the cells
were healthy (see also Supplementary Figure 3). The asso-
ciation of ubiquitin epitopes with WldS also depended on
the N16 sequence, suggesting it is secondary to VCP binding
to WldS (Figure 5, I–P).
An alternative explanation for the accumulation of ubiq-
uitin epitopes at these sites could be ubiquitination of the
WldS/EGFP fusion protein, so we looked for these putative
ubiquitinated species by Western blotting (Figure 6). Wld-18
antibody detected only a single band of the expected size,
even on long-exposure ECLs after a generalized accumula-
tion of ubiquitination products due to proteasome inhibi-
tion. The intensity of the WldS band did increase after pro-
teasome inhibition, suggesting that WldS protein is
degraded by the UPS but despite this, ubiquitinated WldS
did not reach detectable levels on the Western blots. Al-
though we cannot rule out the possibility that ubiquitinated
WldS contributes to the ubiquitin speckles, the inability to
detect this putative species on a Western blot and the prob-
able dependence on VCP binding suggest that putative
ubiquitination of WldS is unlikely to be the sole explanation
for the ubiquitin speckles. Thus, we propose that polyubiq-
uitinated proteins may accumulate in the WldS/VCP com-
plex.
VCP Binding to N16 Is an Evolutionary “Recent”
Development
An alignment of human Ube4b with known orthologues
shows that an N-terminal extension containing the N16 se-
quence is present in mammals, birds, fish, and insects, but
this entire region is absent in nematodes, slime molds, and
yeasts (Figure 7). Nevertheless, the VCP ortholog Cdc48
Figure 2. WldS partially relocalizes VCP in
vitro and in vivo. (A–C) PC12 cells transiently
transfected with WldS/EGFP fusion con-
struct. (A) WldS/EGFP shows a punctate
intranuclear pattern in transfected cells (ar-
rowhead). Arrow marks nucleus of an un-
transfected cell. (B) VCP immunocytochemis-
try reveals the same pattern of intranuclear
foci in transfected cells (arrowhead) together
with widespread nuclear and cytoplasmic
staining. Untransfected cells show only the
wider nuclear and cytoplasmic signal (arrow).
(C) Overlay, together with DAPI stain, con-
firms that the WldS and VCP puncta colocal-
ize within nuclei. The specificity of the stain-
ing and the healthy status of the cells is
demonstrated in Supplementary Figures 1
and 3. (D–I) Double immunofluorescence
staining of sections of WldS and wild-type
mouse cerebellum with WldS (green) and
VCP (red). (D) As in PC12 cells, WldS local-
izes in mouse cerebellar granule cells and mo-
lecular layer neurons to intranuclear spots,
although there are fewer spots per nucleus
than in most PC12 cells (arrowheads). Pur-
kinje cells (arrow) appear not to express WldS.
(E) Immunostaining for VCP reveals the same
pattern of spots as WldS (arrowheads), as well
as staining both cytoplasm and nuclei of the
large Purkinje cells (arrow). (F) Overlay, to-
gether with To-pro3 nuclear stain (blue), con-
firms that the WldS and VCP puncta colocal-
ize within nuclei. (G) WldS antibody showed
no specific stain in wild-type cerebellum. (H) VCP intranuclear foci were not found in cerebellar granule cells or molecular layer neurons in
wild-type mice. The faintly stained Purkinje cells (arrow) confirm that E and H were similarly processed and that cells were healthy. (I)
Overlay, together with To-pro3 stain, indicates the position of nuclei that lack WldS protein. The nonhomogeneous staining by DAPI in C and
to-pro3 in F and I reflects nonhomogeneous distribution of heterochromatin (Wu et al., 2005). Scale bars, 10 m. Each figure is representative
of four or more experiments.
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does bind Ufd2 in Saccharomyces cerevisiae (Koegl et al., 1999;
Richly et al., 2005) and Caenorhabditis elegans (C. Ka¨hler and
T. Hoppe, personal communication) so the interaction in
these species must have a different molecular basis. The
Cdc48 binding site in S. cerevisiae has been mapped (Richly
et al., 2005) and mammals do have a sequence homologous
to it. However, this sequence appears to be insufficient for
VCP binding in human, because N-terminally truncated
Ube4b did not bind VCP (Figure 3A). Mammalian Ube4b
was previously reported to bind VCP (Meyer et al., 2000;
Kaneko et al., 2003) but the interacting sequence was not
fully mapped. Our data show that VCP binds to N16, and
this appears to be a recent event in evolutionary terms with
distantly related higher eukaryotes employing a different
mode of interaction.
DISCUSSION
We report direct binding between VCP and the N-terminal
16 amino acids of WldS protein (N16) that drives partial
redistribution of VCP in nuclei in vivo and in vitro when
full-length WldS is present. N16 is necessary and sufficient
for VCP binding and is necessary for relocalization of VCP,
but is not required to target WldS to discrete intranuclear
foci. Thus, sequences outside N16 cause WldS to accumulate
at these sites and VCP is redistributed through binding to
N16. The N-terminal domain of WldS also influences the
intranuclear distribution of the covalently attached Nmnat1
sequence and hence the distribution of nuclear NAD syn-
thesis machinery.
A recent report indicates that Nmnat1, but not N70, is
sufficient to confer a WldS-like phenotype on neurons in
vitro (Araki et al., 2004). However, the relative strengths of
the neuroprotective phenotypes induced by Nmnat1 and
WldS were not tested and Nmnat1 was not shown to protect
in vivo, where WldS robustly protects longer axons for far
greater time periods (Mack et al., 2001; Adalbert et al., 2005).
Our data show that N70 is not an inert addition to Nmnat1,
but instead concentrates VCP, NAD synthesis activity and
probably its associated ubiquitinated proteins into sub-
Figure 3. VCP binds within the first 16 residues of WldS. (A) Left: truncated GST fusion constructs of WldS and Ube4b. Right top,
autoradiogram of 35S-labeled, IVTT expressed VCP pulled down with these constructs; right bottom, corresponding Coomassie-stained gel.
Constructs a, b, and c, containing the first 23 residues, were able to pull down VCP, but the more C-terminal constructs d and e were not.
The region necessary and sufficient for binding was subsequently narrowed to amino acids 1–16 using constructs f and g. Ube4b also pulled
down VCP but failed to bind when this sequence was removed. Note that very little soluble full-length GST-Ube4b could be recovered by
this method. However, this was sufficient to pull down VCP (lane h), whereas a greater amount of truncated GST-Ube4b (lane i) was not.
(B–E) Full-length WldS/DsRed2 fusion protein partially redistributes VCP/EGFP fusion protein in the PC12 subline TV. (B) Transiently
transfected WldS/DsRed2 fusion protein. (C) Stably transfected VCP/EGFP fusion protein. (D) DAPI. (E) Overlay. In cells not transfected by
WldS/DsRed2, VCP/EGFP (arrow in C), like endogenous VCP (Supplementary Figure 6), is expressed throughout the cytoplasm and most
of the nucleus as previously reported (Hirabayashi et al., 2001; Kobayashi et al., 2002). In cells transfected by WldS/DsRed2, VCP/EGFP signal
colocalizes with the punctate intranuclear pattern of WldS/DsRed2 (arrowheads in B and C), while retaining the cytoplasmic and nuclear
VCP signal. (F–I) WldS/DsRed2 fusion protein truncated by 16 amino acids at the N-terminus does not alter VCP distribution. (F) Transiently
transfected, N-terminally truncated WldS/DsRed2 fusion protein. (G) Stably transfected VCP/EGFP fusion protein. (H) DAPI. (I) Overlay.
VCP/EGFP distribution in the absence of truncated WldS/DsRed2 is similar to that in C (arrow in G). Although truncated WldS/DsRed2 still
shows a punctate intranuclear distribution (arrowhead in F), it does not alter the distribution of VCP/EGFP (arrowhead in G). Scale bar, 10
m. Figures are representative of two (A) or three (B–I) experiments.
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nuclear sites, functions that each have potential to influence
the strength of the WldS phenotype. Thus, WldS joins a
growing list of chimeric proteins whose biological activity
amounts to more than the sum of their parts (Fujimoto et al.,
1996; Campbell et al., 1997; Blume-Jensen and Hunter, 2001).
Further studies are needed to test whether VCP binding is
required for the neuroprotective WldS phenotype, but this
possibility was upheld in two important tests. First, WldS
and VCP show colocalization in at least some DRG neurons
known to express the neuroprotective phenotype, as well as
in cerebellum where the phenotype in vivo remains to be
tested. Second, colocalization was conserved across species
in DRG of WldS rats (Adalbert et al., 2005). The more homo-
geneous intranuclear distribution of WldS in motor neurons
in vivo makes colocalization in this cell type more difficult to
test (Mack et al., 2001; Samsam et al., 2003). Cultured motor
neurons electroporated with WldS/EGFP show WldS puncta
without obvious colocalization of VCP but this does not
exclude a role for VCP in the neuroprotective phenotype in
vivo (Supplementary Figure 5).
Colocalization studies cannot ultimately answer the ques-
tion of whether VCP is required for the WldS phenotype.
Unfortunately, VCP knockout mice are not available to test
the hypothesis and a more complex strategy may be needed.
Given the essential role of VCP in endoplasmic reticulum-
associated protein degradation (ERAD) and several reports
of damaging effects of VCP RNAi, mutation, and deletion in
other species or cell lines, it is unlikely that such knockout
mice would be viable (Hirabayashi et al., 2001; Kobayashi et
al., 2002; Wojcik et al., 2004; Yamanaka et al., 2004). In con-
trast, WldS alters VCP in a way that leaves all cells and
organisms healthy, with no overt harmful effect in the orig-
Figure 4. Nmnat1 is not sufficient to target WldS protein to in-
tranuclear foci. C-terminal EGFP fusion constructs transiently trans-
fected into COS cells. (A) WldS/EGFP localizes primarily to discrete
intranuclear foci (arrowhead), although some remains homoge-
neously distributed inside the nucleus (arrow). (B) Nmnat1/EGFP is
homogeneously distributed, apart from exclusion from nucleoli.
N70/EGFP (C) and EGFP (D) alone are homogeneously distributed
throughout the cell but EGFP has a preference for the nucleus as
previously described (Alonso et al., 2004). Neither is targeted to
intranuclear foci. Scale bar, 10 m. Figures are representative of
three experiments.
Figure 5. Full-length WldS can also par-
tially relocalize ubiquitin inside the nucleus.
(A) PC12 cells transiently transfected with
WldS/EGFP fusion construct show a punc-
tate intranuclear distribution (arrowheads),
whereas untransfected cells show no signal
(arrow). (B) Ubiquitin immunofluorescence
shows colocalizing punctate signal in trans-
fected cells (arrowheads), together with a
widespread nuclear and cytoplasmic signal.
Untransfected cells show only the more ho-
mogenous distribution (arrow). (C) DAPI.
(D) Overlay. (E and F) Control experiment in
which the first antibody against ubiquitin
was omitted. Transfected cells (arrow) show
no signal in the red channel. Panel order
corresponds to A–D as indicated. Scale bar,
10 m. (I–P) A repeat of the experiment in
Figure 3 but immunostaining for ubiquitin
instead of VCP. Ubiquitin shows the same
dependence on N16 for colocalization with
WldS/DsRed2 in intranuclear spots. (I–L)
Transfection with full-length WldS/DsRed2
results in partial colocalization, which is re-
tained when the confocal image stack is ro-
tated (arrowheads in L). (M–P) Transfection
with N-terminally truncated WldS/DsRed2
does not result in colocalization. The small
region of overlapping signal (arrow in P) is
not retained when the confocal image stack is
rotated. (I and M) DAPI staining shows po-
sition of nuclei; (J and N) ubiquitin immuno-
stain. (K and O) DsRed2 signal fused, respec-
tively, to full-length WldS and WldS lacking
N16. (L and P) Overlays.
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inal mutant (Lunn et al., 1989), four lines of transgenic mice
(Mack et al., 2001), three of rats (Adalbert et al., 2005) or in
double homozygous mice or rats (unpublished observa-
tions). This is likely to reflect the confinement of alterations
to the nucleus, leaving the essential role of VCP in ERAD
unaffected.
Studies in yeast suggest VCP stimulates substrate binding
but limits the subsequent growth of a polyubiquitin chain
(Richly et al., 2005). However, VCP is dispensable for Ube4b
activity when concentrated preparations of protein are used
in vitro (Hatakeyama et al., 2001; Mahoney et al., 2002) and in
these circumstances removal of the N-terminal 123 amino
acids of Ube4b blocks activity for unknown reasons (Ma-
honey et al., 2002). Our data further highlight the importance
of the N-terminus of Ube4b as a regulatory sequence. Many
invertebrates lack this sequence but still bind the VCP or-
tholog Cdc48, so this molecular interaction appears to have
changed during evolution.
VCP plays pivotal roles in ERAD, nuclear envelope recon-
struction, cell cycle, postmitotic Golgi reassembly, and sup-
pression of apoptosis (Kondo et al., 1997; Dai and Li, 2001;
Hetzer et al., 2001; Rabinovich et al., 2002; Wang et al., 2004).
Its nuclear functions are equally diverse. First, a nuclear
transport role is suggested by its association with adapter
proteins Ufd1 and Np14, and by VCP-dependent transport
of T-cell-specific adaptor protein into eukaryotic nuclei
(Meyer et al., 2000; Marti and King, 2005). Second, VCP
controls nucleolar retention of Werner syndrome helicase
and its release after DNA damage (Indig et al., 2004). Inter-
estingly, our data fit with the proposal of these authors that
other nuclear binding partners regulate VCP distribution
and control other pathways. Third, the nucleus has a quality
control pathway (Gardner et al., 2005) likely to involve VCP.
Interaction and colocalization with expanded polyglutamine
and other intranuclear inclusions suggests VCP may be try-
ing to clear misfolded nuclear proteins (Hirabayashi et al.,
2001; Doss-Pepe et al., 2003; Mizuno et al., 2003). Finally, VCP
regulates the stability of the transcription factor SPT23
(Richly et al., 2005), consistent with the tight regulation of
transcription by the UPS (Muratani and Tansey, 2003).
VCP is altered in several neurodegenerative disorders so
its interaction with the neuroprotective WldS protein is
particularly interesting. VCP missense mutations cause in-
clusion body myopathy with Paget disease of bone and
frontotemporal dementia, a disease characterized by ubiq-
uitin-containing nuclear inclusions and white matter pathol-
ogy (Watts et al., 2004; Schroder et al., 2005). VCP is present
in Lewy-like inclusions in amyotrophic lateral sclerosis, in
nigral Lewy neurites in Parkinson’s disease (Ishigaki et al.,
2004), and in ubiquitin-positive intraneuronal inclusions in
motor neuron disease with dementia, ballooned neurons in
Creutzfeldt-Jakob disease, and dystrophic neurites of senile
plaque in Alzheimer’s disease (Mizuno et al., 2003). In poly-
glutamine disorders such as Huntington’s disease and
Machado-Joseph disease, specific binding to expanded poly-
glutamine targets VCP to intranuclear inclusions (Hiraba-
Figure 6. Ubiquitinated WldS protein cannot be detected. (A)
Western blotting with antibody to WldS protein did not detect any
ubiquitinated WldS/EGFP fusion protein or ubiquitinated WldS in
transfected PC12 cells (left) or in WldS mouse cerebellum (right),
respectively. The 70- and 43-kDa bands correspond to the predicted
molecular weights of the unmodified proteins. (B) The proteasome
inhibitor MG-132 (10 M for times shown) caused ubiquitination
products to build up in PC12 cells (left), but ubiquitinated WldS/
EGFP (70 kDa) still could not be detected even on an overexposed
ECL (right). Figures are representative two experiments.
Figure 7. VCP binding to N16 is an evolu-
tionary “recent” event. (A) Full-length align-
ment of Ube4b and Ufd2 sequences. (B)
Amino acid alignment of N16-like or other
N-terminal sequences in the same proteins.
The database accession numbers are also
shown. Mammals, birds, fish, and insects
have sequence showing significant homology
to the VCP binding site in N16 at positions
denoted by the asterisk (*). Nematodes, slime
molds, and yeasts lack the entire N-terminal
extension containing this sequence. The
Cdc48 binding site of S. cerevisiae Ufd2p
(Richly et al., 2005), the U box (Hatakeyama et
al., 2001), and the sequence essential for in
vitro ubiquitination activity (Mahoney et al.,
2002) are also marked. Black boxes, regions of
significant homology to human Ube4b; open
boxes, regions not homologous to human
Ube4b; bold, amino acids identical to human
sequence; underlined, conservative substitu-
tions.
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yashi et al., 2001). This interaction appears to influence dis-
ease severity, as loss-of-function mutations in the Drosophila
VCP ortholog, ter4, dominantly suppress neurodegeneration
caused by expanded polyglutamine (Higashiyama et al.,
2002).
It is now important to determine whether WldS protein, or
N70 can interfere with the effect of VCP in any of these
neurodegenerative disorders. Ectopic expression in Drosoph-
ila of mammalian Ube4b suppresses polyglutamine disease,
and loss of function mutations in VCP have a similar effect
(Higashiyama et al., 2002; Matsumoto et al., 2004). It is also
now clear that WldS and expanded polyglutamine both bind
VCP directly and partially relocalize it to intranuclear foci
(Hirabayashi et al., 2001). Taken together, these observations
raise the intriguing possibility that N70 and VCP antagonize
each other in some circumstances as a result of the binding
interaction we describe.
In summary, we report direct interaction between VCP
and the N-terminal 16 amino acids of both WldS and Ube4b
proteins. This interaction drives focal intranuclear clustering
of VCP in WldS neurons, probably together with associated
multiubiquitinated proteins, and helps understand the func-
tion of an important, evolutionarily recent regulatory se-
quence in the Ube4b protein. It is now important to deter-
mine whether the redistribution of covalently attached
Nmnat1 or of bound VCP influences the strength of the
WldS phenotype in vivo and to understand how the N-
terminal binding of VCP to Ube4b influences this ubiquitin
ligase.
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